Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc.

Kepler Capital analyst Alessandro Cuglietta maintained a Buy rating on Abeo SA on December 10 and set a price target of €25.00. The company’s share...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABEO	$5.36	-2.90%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABEO	$5.36	-2.9%	1.02M
3
4
5
6

ABEO

ABEO

Latest News for ABEO

Get Abeona Therapeutics Inc. Data in Excel

Get Abeona Therapeutics Inc. Data in Excel